EpimAb Biotherapeutics, Inc.
Advancing a Best-in-class Bispecific Antibody Format
40 employees · est. 2015 · Shanghai, China
EpimAb Biotherapeutics, Inc. is the older company (2018 vs 2015).
Side-by-Side Comparison
| Metric | DotBio | EpimAb Biotherapeutics, Inc. |
|---|---|---|
| Founded | ||
| Founded | 2018 | 2015 older |
| Headquarters | ||
| Headquarters | Singapore, Singapore | Shanghai, China |
| Employees | ||
| Employees | 18 | 40 |
| Industry | ||
| Industry | Biotechnology, Life Sciences | Biopharma, Biotechnology, Health Care |
| Funding Stage | ||
| Funding Stage | Seed | Series C |
| Total Funding | ||
| Total Funding | $8.15M | $219.00M |
| Funding Rounds | ||
| Funding Rounds | 4 | 3 |
| Services | ||
| Services | Not tracked yet | Not tracked yet |
| Target Customers | ||
| Target Customers | Not tracked yet | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Immuno-oncology Drugs, Domain Antibodies, DotBody Technology, Multi-specific Antibodies, Humanized Antibodies, Stable Antibodies, Protein Engineering, Antibody Engineering, Biopharmaceuticals, Cancer Treatment, Therapy Development, Drug Development, Therapeutic Antibodies, Medical Research | Biopharmaceuticals, Bi-specific Antibodies, Oncology Therapeutics, Immuno-oncology, Monoclonal Antibodies, FIT-Ig Platform, CMC Development, Licensing Arrangements, Series A Funding, Drug Development, Pharmaceutical Industry, Novel Bi-specific Antibodies, China-based Startup, International Investors, Clinical Development |
| Website | ||
| Website | dotbiopharma.com | epimab.com |
About DotBio
DotBio is a Singapore-based biotechnology startup founded in 2018. The company focuses on developing innovative immuno-oncology drugs utilizing their proprietary DotBodies technology. This technology, conceived by Professor Pär Nordlund and Dr. Ignacio Asial at Singapore’s Nanyang Technological Univ...
About EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics, Inc., a China-based biopharmaceutical startup founded in 2015, is making strides in developing novel bi-specific antibodies in the fields of oncology and immune-oncology. The company's proprietary platform, FIT-Ig (Fabs in Tandem), has successfully produced multiple bispecifi...
We will tell you when either one moves
BounceWatch watches DotBio and EpimAb Biotherapeutics, Inc. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at DotBio and EpimAb Biotherapeutics... — by email.
Frequently Asked Questions
Compare DotBio with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at DotBio on 12 Sep 2024, and EpimAb Biotherapeutics, Inc. on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
